Development of KSQ-4279 as a first-in-class USP1 inhibitor for the treatment of BRCA-deficient cancers
Cadzow, L., Brenneman, J., Sullivan, P., Liu, H., Shenker, S., McGuire, M., Grasberger, P., Sinkevicius, K., Hafeez, N., Histen, G., Chipumuro, E., Hixon, J., Krall, E., Cogan, S., Wilt, J., SchlabachVolume:
138
Journal:
European Journal of Cancer
DOI:
10.1016/S0959-8049(20)31215-6
Date:
October, 2020
File:
PDF, 33 KB
2020